After Zydus' Historic COVID-19 DNA Vaccine Approval, Inovio To Enter Phase III
Will Data Availability Hold Key To Acceptance?
Soon after Zydus Cadila won a historic accelerated approval in India for the world’s first plasmid DNA vaccine for human use, in this case against COVID-19, Inovio’s candidate is set to move to Phase III in Brazil. But will the new technology find wide acceptance?
You may also be interested in...
As a new Delta plus variant is identified, India’s exemption of bridging trials for imported COVID-19 vaccines could help speed up immunization efforts. The urgency to fully immunize individuals could also prompt a reduction in the interval between Serum/AstraZeneca’s COVID-19 vaccine doses
Inovio looks to countries outside the US to continue late-stage development of its vaccine, while a South Korean firm strikes a supply deal with Indonesia and Japan approves a new drug for COVID-19.
India has given conditional accelerated approval to AstraZeneca partner Serum Institute, and separately to Bharat Biotech, for their COVID-19 vaccines. With the latter’s candidate still in Phase III trials, the unprecedented decision has caused controversy given the national regulator had earlier said an EUA would not be granted unless trials are completed.